Fresenius Medical Care AG & Co. (NYSE:FMS) hit a new 52-week low during mid-day trading on Tuesday after SunTrust Banks lowered their price target on the stock to $46.00. SunTrust Banks currently has a buy rating on the stock. Fresenius Medical Care AG & Co. traded as low as $37.53 and last traded at $37.75, with a volume of 4050 shares changing hands. The stock had previously closed at $39.01.

FMS has been the subject of a number of other research reports. Zacks Investment Research lowered shares of Fresenius Medical Care AG & Co. from a “hold” rating to a “sell” rating in a research note on Friday, August 3rd. Royal Bank of Canada reaffirmed a “neutral” rating on shares of Fresenius Medical Care AG & Co. in a research note on Friday, August 17th. ValuEngine lowered shares of Fresenius Medical Care AG & Co. from a “hold” rating to a “sell” rating in a research note on Wednesday, October 17th. HSBC raised shares of Fresenius Medical Care AG & Co. from a “hold” rating to a “buy” rating in a research note on Tuesday, August 28th. Finally, DZ Bank reaffirmed a “buy” rating on shares of Fresenius Medical Care AG & Co. in a research note on Monday, August 6th. One analyst has rated the stock with a sell rating, five have given a hold rating and six have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $62.00.

Several hedge funds have recently added to or reduced their stakes in the stock. Bank of Montreal Can lifted its stake in shares of Fresenius Medical Care AG & Co. by 1.5% in the 3rd quarter. Bank of Montreal Can now owns 86,399 shares of the company’s stock valued at $4,442,000 after purchasing an additional 1,276 shares during the last quarter. Greenleaf Trust lifted its stake in shares of Fresenius Medical Care AG & Co. by 15.3% in the 2nd quarter. Greenleaf Trust now owns 9,912 shares of the company’s stock valued at $499,000 after purchasing an additional 1,316 shares during the last quarter. Eagle Global Advisors LLC lifted its position in Fresenius Medical Care AG & Co. by 2.5% during the 2nd quarter. Eagle Global Advisors LLC now owns 60,560 shares of the company’s stock worth $3,049,000 after acquiring an additional 1,500 shares during the last quarter. FDx Advisors Inc. lifted its position in Fresenius Medical Care AG & Co. by 9.3% during the 2nd quarter. FDx Advisors Inc. now owns 19,455 shares of the company’s stock worth $980,000 after acquiring an additional 1,650 shares during the last quarter. Finally, Ferguson Wellman Capital Management Inc. lifted its position in Fresenius Medical Care AG & Co. by 1.2% during the 3rd quarter. Ferguson Wellman Capital Management Inc. now owns 147,890 shares of the company’s stock worth $7,605,000 after acquiring an additional 1,726 shares during the last quarter. 2.53% of the stock is owned by institutional investors and hedge funds.

The stock has a market capitalization of $24.61 billion, a price-to-earnings ratio of 16.98, a price-to-earnings-growth ratio of 1.78 and a beta of 1.10. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.00 and a current ratio of 1.24.

Fresenius Medical Care AG & Co. (NYSE:FMS) last released its earnings results on Tuesday, October 30th. The company reported $0.69 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.58 by $0.11. The firm had revenue of $4.72 billion during the quarter. Fresenius Medical Care AG & Co. had a net margin of 11.71% and a return on equity of 10.87%. As a group, equities research analysts anticipate that Fresenius Medical Care AG & Co. will post 2.52 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece was posted by Daily Political and is the property of of Daily Political. If you are accessing this piece on another publication, it was illegally copied and republished in violation of United States & international copyright and trademark law. The legal version of this piece can be accessed at https://www.dailypolitical.com/2018/11/20/fresenius-medical-care-ag-co-fms-hits-new-52-week-low-after-analyst-downgrade.html.

About Fresenius Medical Care AG & Co. (NYSE:FMS)

Fresenius Medical Care AG & Co KGaA provides products and services for patients with chronic kidney failure. The company’s products include dialysis machines, dialyzers and related disposables. It also offers renal information technology solutions and provides services such as renal replacement therapy and therapeutic apheresis.

Recommended Story: Is the Dow Jones Industrial Average (DJIA) still relevant?

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.